Stock Report

All about this stock under one free report Last Updated: 06-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Bright Minds Biosciences Inc (DRUG) Key Ratios

Stock Card factsheet share-fund-plan-icon

$65.16

up-down-arrow $-2.86 (-4.20%)

As on 04-Sep-2026 16:10EDT

Market cap

info icon

$714 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

3.3

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -- --
EBIT -10.39 -123.79 -264.98 -223.00 -197.68
Net Profit 76.85 53.05 -177.52 -193.23 -214.80
EPS 77.42 66.16 -89.76 -4.51 3.67
Book Value -- -- 861.21 47.94 80.46
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMSep-25Sep-24
EBIT-Margin info ----------
Net Margin info ----------
Return on equity info -53.38-68.94-12.45-27.93-46.18
Return on Capital info -52.76-68.47---27.85-45.46
Return on Assets info -49.31-64.50-7.34-27.02-43.16
Debt to Equity (x) info ----0.000.000.02

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Sep-25
Sep-24
Sep-23
Sep-22
Bright Minds Biosciences Inc (DRUG)
--
-27.85
-45.46
-84.96
-99.49
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-12.45

Higher than Peers by 38.49

Profit after tax / Average Net worth * 100

Company Name
TTM
Sep-25
Sep-24
Sep-23
Sep-22
Bright Minds Biosciences Inc (DRUG)
-12.45
-27.93
-46.18
-86.02
-99.95
Peer Median
-50.94
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-7.34

Higher than Peers by 39.50

Profit after tax / Average Total assets * 100

Company Name
TTM
Sep-25
Sep-24
Sep-23
Sep-22
Bright Minds Biosciences Inc (DRUG)
-7.34
-27.02
-43.16
-77.74
-93.16
Peer Median
-46.84
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

EBIT Growth

-264.98

Lower than Peers by 228.83

Year on year growth in operating profit (EBIT)

Company Name
TTM
Sep-25
Sep-24
Sep-23
Sep-22
Bright Minds Biosciences Inc (DRUG)
-264.98
-336.46
61.99
50.74
-70.86
Peer Median
-36.16
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-177.52

Lower than Peers by 128.55

Year on year growth in profit after tax

Company Name
TTM
Sep-25
Sep-24
Sep-23
Sep-22
Bright Minds Biosciences Inc (DRUG)
-177.52
-336.46
61.99
50.74
-75.74
Peer Median
-48.96
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-89.76

Lower than Peers by 98.17

Year on year growth in earnings per share

Company Name
TTM
Sep-25
Sep-24
Sep-23
Sep-22
Bright Minds Biosciences Inc (DRUG)
-89.76
-1.83
0.69
0.61
-0.39
Peer Median
8.42
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

328.64

Higher than Peers by 188.47

Year on year growth in book value per share

Company Name
TTM
Sep-25
Sep-24
Sep-23
Sep-22
Bright Minds Biosciences Inc (DRUG)
328.64
--
--
--
--
Peer Median
140.17
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Sep-25
Sep-24
Sep-23
Sep-22
Bright Minds Biosciences Inc (DRUG)
--
0.00
0.02
0.01
0.01
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.00

--

(Short term borrowings / Net worth)

Company Name
TTM
Sep-25
Sep-24
Sep-23
Sep-22
Bright Minds Biosciences Inc (DRUG)
0.00
0.00
0.01
0.01
0.01
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

121.97

Higher than Peers by 116.13

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Sep-25
Sep-24
Sep-23
Sep-22
Bright Minds Biosciences Inc (DRUG)
121.97
36.10
11.32
24.26
8.11
Peer Median
5.84
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

121.97

Higher than Peers by 116.13

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Sep-25
Sep-24
Sep-23
Sep-22
Bright Minds Biosciences Inc (DRUG)
121.97
--
--
24.39
--
Peer Median
5.84
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-1,513.67

Lower than Peers by 1,485.59

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Sep-25
Sep-24
Sep-23
Sep-22
Bright Minds Biosciences Inc (DRUG)
-1,513.67
-475.09
--
-373.28
-67.17
Peer Median
-28.08
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Asset Turnover

--

--

Sales / Average Total Assets

Company Name
TTM
Sep-25
Sep-24
Sep-23
Sep-22
Bright Minds Biosciences Inc (DRUG)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Sep-25
Sep-24
Sep-23
Sep-22
Bright Minds Biosciences Inc (DRUG)
--
--
--
-186.44
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Sep-25
Sep-24
Sep-23
Sep-22
Bright Minds Biosciences Inc (DRUG)
--
7,007.85
--
3,601.31
55,751.20
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...